ClinicalTrials.gg
RecruitingNCT07481630AMAZE 5Updated Jul 9, 2026

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

A Phase 3 interventional study of NNC0487-0111 and Placebo (matched to NNC0487-0111 ) in Obesity and Knee Osteoarthritis (OA), sponsored by Novo Nordisk A/S. Recruiting at 82 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing zenagamtide in Obesity — 17 open to participants now, 20 under way, 14 of them phase 3. zenagamtide · Obesity.

Planned enrollment
9th of 24
400 · median 360
Started
2026
with 18 others
Phase 3
14 of 24
11 open now
Primary completion
2028-08
later than 7 of 19 live
Registered
7th of 24
by date
Lead sponsor
24 of 24
Novo Nordisk A/S

Among the 24 studies testing zenagamtide in Obesity, this one is the 9th largest by planned enrollment, is one of 19 that started in 2026, is one of 14 in phase 3, reaches primary completion later than 7 of the 19 other live ones, and was the 7th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

17 of the 24 studies testing zenagamtide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About zenagamtide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing zenagamtide in Obesity, or all of them as a file.
02

Study summary

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee osteoarthritis. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

03

Conditions studied

  • Obesity
  • Knee Osteoarthritis (OA)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion Criteria:

  • Male or female (sex at birth).
  • Age 18 years or above at the time of signing the .
  • Clinical diagnosis of knee osteoarthritis (American College of Rheumatology criteria) with radiographic changes (Kellgren Lawrence (KL) grades 2 to 3 as per central reading) in target knee. Target knee joint is defined as most symptomatic knee at screening. If pain in knees is equal, the target knee joint will be the dominant leg.
  • Symptomatic knee OA with first appearance of pain in the target knee more than (>) 90 days prior to screening and pain in the target knee for > 15 days over the prior 30 days.
  • Willingness to complete a 72-hour of analgesics before all visits involving WOMAC Osteoarthritis Index NRS 3.1 (24-hour) (WOMAC) questionnaire (acetaminophen 4 gram (g)/day is allowed as rescue medication up until 24 hours before those visits).

Exclusion Criteria:

  • more than or equal to (≥) 6.5% [(48 millimoles per mole (mmol/mol)] as measured by the central laboratory at screening.
  • History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.
  • Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues before screening.
  • Any joint prosthesis or joint replacement in target knee.
  • Arthroscopy or injections into target knee within the last 90 days prior to screening.
  • Any other joint disease in target knee including gout and pseudogout.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    NNC0487-0111 dose level 1

    Participants will be randomized to receive NNC0487-0111 dose level 1 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.

    Drug: NNC0487-0111

  • Experimental
    NNC0487-0111 dose level 2

    Participants will be randomized to receive NNC0487-0111 dose level 2 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.

    Drug: NNC0487-0111

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to NNC0487-0111 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.

    Drug: Placebo (matched to NNC0487-0111 )

Interventions

  • NNC0487-0111 dose level 1 and dose level 2 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

  • DrugPlacebo (matched to NNC0487-0111 )

    Placebo matched to NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

06

What researchers measure

Primary outcomes

  1. Relative change in body weight

    Measured as percentage (%) of body weight.

    Time frame: From baseline (week 0) to (week 80)

  2. Change in WOMAC Osteoarthritis Index NRS 3.1 (24-hour) (WOMAC) pain score

    Measured as score on a scale. Western Ontario and McMaster Universities Arthritis Index (WOMAC) measures symptoms in the areas of pain, stiffness, and physical function. The measure consists of 24 items yielding 3 subscale scores and 1 total score. WOMAC raw scores are transformed to a standardised 0 to 100 score range. Higher scores indicate worse pain, stiffness, physical function, and overall osteoarthritis- related disability.

    Time frame: From baseline (week 0) to (week 80)

Secondary outcomes

  1. Change in WOMAC physical function score

    Measured as score on a scale. Physical function score will be calculated according to the guidelines provided in the WOMAC User Guide XI. Score ranges from 0-100 and higher scores indicate worse physical function.

    Time frame: From baseline (week 0) to (week 80)

  2. Change in SF-36v2® Health Survey Acute (SF-36v2 Acute) physical functioning score

    Measured as score on a scale. SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation (SD) of 10. Higher scores indicate better functional health and well-being. The physical functioning ranges from 19.0 to 57.6.

    Time frame: From baseline (week 0) to (week 80)

  3. Change in body weight

    Measured as kilogram (kg).

    Time frame: From baseline (week 0) to (week 80)

  4. Change in body mass index (BMI)

    Measured as kilograms per meter squared (kg/m\^2).

    Time frame: From baseline (week 0) to (week 80)

  5. Change in WOMAC stiffness score

    Measured as score on a scale. Stiffness score will be calculated according to the guidelines provided in the WOMAC User Guide XI. Score ranges from 0-100 and higher scores indicate worse stiffness.

    Time frame: From baseline (week 0) to (week 80)

  6. Change in WOMAC total score

    Measured as score on a scale. Total score will be calculated according to the guidelines provided in the WOMAC User Guide XI. Total score ranges from 0-100 and higher scores indicate worse overall osteoarthritis- related disability.

    Time frame: From baseline (week 0) to (week 80)

  7. Change in waist circumference

    Measured as centimetre (cm).

    Time frame: From baseline (week 0) to (week 80)

  8. Change in systolic blood pressure (SBP)

    Measured as millimetre of mercury (mmHg).

    Time frame: From baseline (week 0) to (week 80)

  9. Change in diastolic blood pressure (DBP)

    Measured as mmHg.

    Time frame: From baseline (week 0) to (week 80)

  10. Change in total cholesterol

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to (week 80)

  11. Change in high-density lipoprotein (HDL) cholesterol

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to (week 80)

  12. Change in low-density lipoprotein (LDL) cholesterol

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to (week 80)

  13. Change in very low-density lipoprotein (VLDL) cholesterol

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to (week 80)

  14. Change in non-HDL cholesterol

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to (week 80)

  15. Change in triglycerides

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to (week 80)

  16. Change in high-sensitivity C-reactive protein (hsCRP)

    Measured as ratio to baseline.

    Time frame: From baseline (week 0) to (week 80)

  17. Change in glycated haemoglobin (HbA1c)

    Measured as percentage (%) of HbA1c.

    Time frame: From baseline (week 0) to (week 80)

  18. Change in fasting plasma glucose (FPG)

    Measured as millimole per liter (mmol/L).

    Time frame: From baseline (week 0) to (week 80)

  19. Number of participants allowed using rescue analgesics during washout period (Yes/no)

    Measured as number of participants

    Time frame: From baseline (week 0) to (week 80)

  20. Amount of allowed rescue analgesics used during washout period

    Measured as dose of analgesics.

    Time frame: From baseline (week 0) to (week 80)

  21. Use of pain medication (Yes/No)

    Measured as number of participants.

    Time frame: From baseline (week 0) to (week 80)

  22. Amount of pain medication used

    Measured as dose of pain medication.

    Time frame: From baseline (week 0) to (week 80)

  23. Number of participants with change in pain medication (decrease/no change/increase)

    Measured as number of participants.

    Time frame: From baseline (week 0) to (week 80)

  24. Change in knee pain intensity (NRS)

    Measured as score on a scale. Knee pain numerical rating scale (NRS) measures knee pain at its worst in the last 24 hours. The measure consists of 1 item. The response scale is an 11-point numeric rating scale from 0 (No knee pain) to 10 (Worst possible knee pain). Higher scores indicate worse pain.

    Time frame: From baseline (week 0) to (week 80)

  25. Number of treatment Emergent Adverse Events (TEAEs)

    Measured as number of events.

    Time frame: From baseline (week 0) to week 84

  26. Number of treatment Emergent Serious Adverse Events (TESAEs)

    Measured as number of events.

    Time frame: From baseline (week 0) to week 84

  27. Number of TEAEs leading to permanent treatment discontinuation

    Measured as number of events.

    Time frame: From baseline (week 0) to week 84

07

Study locations

73 of 82 sites recruiting
  • Arizona Research Center, Inc.
    Phoenix, Arizona 85053, United States
    Recruiting
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
    Recruiting
  • Chase Medical Research LLC
    Hamden, Connecticut 06517, United States
    Recruiting
  • Chase Medical Research LLC
    Waterbury, Connecticut 06708, United States
    Recruiting
  • Zenith clinical research
    Hollywood, Florida 33021, United States
    Recruiting
  • CNS Healthcare
    Jacksonville, Florida 32256, United States
    Recruiting
  • Angels Clinical Research Institute
    Miami Lakes, Florida 33016, United States
    Recruiting
  • Hope Clin Res & Wellness
    Conyers, Georgia 30094, United States
    Recruiting
  • CenExel iResearch, LLC
    Decatur, Georgia 30030, United States
    Recruiting
  • Elite Clinical Trials
    Blackfoot, Idaho 83221, United States
    Recruiting
  • MedVadis Research Watertown
    Waltham, Massachusetts 02451, United States
    Recruiting
  • Jubilee Clinical Research, Inc.
    Las Vegas, Nevada 89106, United States
    Recruiting
  • Great Lakes Medical Research
    Westfield, New York 14787, United States
    Recruiting
  • Accellacare and KDCILM, LLC
    Wilmington, North Carolina 28401, United States
    Recruiting
  • Coastal Carolina Res Ctr
    North Charleston, South Carolina 29405, United States
    Recruiting
  • VIP Trials_San Antonio
    San Antonio, Texas 78230, United States
    Recruiting
  • Charlottesville Med Research
    Charlottesville, Virginia 22911, United States
    Recruiting
  • Health Res of Hampton Roads
    Newport News, Virginia 23606, United States
    Recruiting
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
    Recruiting
  • Emeritus Research Sydney
    Botany, New South Wales 2019, Australia
    Recruiting
  • Momentum Clinical Research Darlinghurst
    Darlinghurst, New South Wales 2010, Australia
    Recruiting
  • Kolling Institute
    St Leonards, New South Wales 2065, Australia
    Recruiting
  • Heart of Australia
    Chelmer, Queensland 4068, Australia
    Recruiting
  • Coastal Digestive Health
    Maroochydore, Queensland 4558, Australia
    Recruiting
  • UMHAT Sveti Georgi EAD, Plovdiv
    Plovdiv, 4002, Bulgaria
    Recruiting
  • MC Dr. Atanasov EOOD
    Sofia, 1231, Bulgaria
    Recruiting
  • MC Excelsior OOD
    Sofia, 1407, Bulgaria
    Recruiting
  • UMHAT Tsaritsa Yoanna - ISUL EAD, Orthopaedics and Traumatology
    Sofia, 1527, Bulgaria
    Recruiting
  • MMA MHAT - Sofia, Rheumatology clinic
    Sofia, 1606, Bulgaria
    Recruiting
  • UMHAT Sveti Ivan Rilski EAD, Rheumatology
    Sofia, 1612, Bulgaria
    Recruiting
  • Laser Rejuvenation Clinics Inc.
    Calgary, Alberta T2W 4X9, Canada
    Recruiting
  • Dawson Clinical Research
    Guelph, Ontario N1H 1B1, Canada
    Recruiting
  • Hamilton Medical Rsrch Grp
    Hamilton, Ontario L8L 5G4, Canada
    Not yet recruiting
  • Centre de Recherche Musculo
    Trois-Rivières, Quebec G8Z 1Y2, Canada
    Recruiting
  • Alpha Recherche Clinique - Lebourgneuf
    Québec, G2J OC4, Canada
    Recruiting
  • Aarhus Universitetshospital - Klinik for Led og bindevævssygdomme
    Aarhus N, 8200, Denmark
    Recruiting
  • Frederiksberg Hospital - Parker Institutet (Artrose)
    Frederiksberg, 2000, Denmark
    Recruiting
  • Sanos Clinic - Herlev
    Herlev, 2730, Denmark
    Recruiting
  • University General Hospital Attikon General Hospital Of West Attica H Agia Varvara - 2nd dept of Internal medicine
    Chaïdári, Attica 12461, Greece
    Recruiting
  • Laiko General Hospital Of Athens - 1st department of Internal Medicine
    Athens, 115 27, Greece
    Recruiting
  • Athens Medical Center S.A. (Iatriko Psychikou) - Department of Internal Medicine & Metabolic Diseases
    Athens, 11525, Greece
    Recruiting
  • General Hospital Of Athens Alexandra - Clinical Therapeutics
    Athens, 11528, Greece
    Recruiting
  • Athens Medical Center S.A. (Iatriko Athinon) - Diabetes and Obesity Unit
    Marousi, 15125, Greece
    Recruiting
  • NextHealth S.A. - Department of Endocrinology, Metabolism & Diabetes
    Thessaloniki, 54635, Greece
    Recruiting
  • Thermi Clinic S.A. - Diabetes and Internal Medicine Department
    Thessaloniki, 57001, Greece
    Recruiting
  • AOU Federico II Di Napoli - DAI Endocr. Diab. Andro. e Nutr. - UOC Medicina Interna e Nutrizione Clinica
    Naples, Campania 80131, Italy
    Recruiting
  • Ospedale Civile di Baggiovara - UOC Endocrinologia
    Modena, Emilia-Romagna 41126, Italy
    Not yet recruiting
  • Ospedale S. Maria della Misericordia - Reparto Endocrinologia e Malattie del Metabolismo
    Udine, Friuli Venezia Giulia 33100, Italy
    Recruiting
  • Pol. Uni. Campus Biomedico - UOC Endocrinologia e Diabetologia
    Rome, Lazio 00128, Italy
    Recruiting
  • Auxologico San Luca - Endocrinologia e Malattie del Metabolismo
    Milan, Lombardy 20149, Italy
    Recruiting
  • Policlinico San Donato di Milano S.p.A - UOS Endocrinologia e del Servizio di Nutrizione Clinica e Prevenzione Cardiometabolica
    San Donato Milanese, Lombardy 20097, Italy
    Recruiting
  • Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Civile Maggiore Borgo Trento - U.O. Reumatologia
    Verona, Veneto 37126, Italy
    Recruiting
  • "Zdrowie Osteo-Medic" s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik
    Bialystok, Podlaskie Voivodeship 15-351, Poland
    Recruiting
  • "Zdrowie Osteo-Medic" s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik
    Bialystok, Podlaskie Voivodeship 15-351, Poland
    Not yet recruiting
  • ClinicMed Daniluk, Nowak Spółka Komandytowa
    Bialystok, 15-879, Poland
    Recruiting
  • ClinicMed Daniluk, Nowak Spółka Komandytowa
    Bialystok, 15-879, Poland
    Not yet recruiting
  • Centrum Medyczne Intercor Sp. z o.o.
    Bydgoszcz, 85-605, Poland
    Recruiting
  • Centrum Medyczne Intercor Sp. z o.o.
    Bydgoszcz, 85-605, Poland
    Not yet recruiting
  • CenterMed Kraków Sp. z o.o.
    Krakow, 31-530, Poland
    Recruiting
  • CenterMed Kraków Sp. z o.o.
    Krakow, 31-530, Poland
    Not yet recruiting
  • Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie Sp. z o.o.
    Krakow, 31-826, Poland
    Recruiting
  • Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie Sp. z o.o.
    Krakow, 31-826, Poland
    Not yet recruiting
  • Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im. prof. dr hab. med. Eleonory Reicher
    Warsaw, 02-637, Poland
    Recruiting
  • Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im. prof. dr hab. med. Eleonory Reicher
    Warsaw, 02-637, Poland
    Not yet recruiting
  • Instituto Medico Quirurgico San Rafael
    A Coruña, 15006, Spain
    Recruiting
  • Hospital Germans Trias i Pujol
    Badalona, 08916, Spain
    Not yet recruiting
  • Hospital Naval Ferrol
    Ferrol, 15405, Spain
    Recruiting
  • Centro Especialidades Hermanos Sangro
    Madrid, 28038, Spain
    Recruiting
  • Hospital Quirónsalud Málaga
    Málaga, 29004, Spain
    Recruiting
  • Hospital Infanta Sofía
    San Sebastián de Los Reyes (Madrid), 28702, Spain
    Recruiting
  • Hospital Universitario Marqués de Valdecilla
    Santander, 39008, Spain
    Recruiting
  • Hospital HM La Esperanza
    Santiago de Compostela, 15705, Spain
    Recruiting
  • Clínica Nuevas Tecnologías en Diabetes y Endocrinología
    Seville, 41003, Spain
    Recruiting
  • H. Infanta Luisa_Endocrino y Obesidad
    Seville, 41010, Spain
    Recruiting
  • Hospital General de Valencia
    Valencia, 46014, Spain
    Recruiting
  • Ankara Üniversitesi Sağlık Uygulama ve Araştırma Hastaneleri- Fiziksel Tıp ve Rehabilitasyon
    Altındağ/Ankara, 06230, Turkey (Türkiye)
    Recruiting
  • İstanbul Fizik Tedavi ve Rehabilitasyon Eğitim ve Araştırma Hastanesi
    Bahçelievler/İstanbul, 34186, Turkey (Türkiye)
    Recruiting
  • Ankara Bilkent Şehir Hastanesi- Fizik Tedavi ve Rehabilitasyon
    Çankaya/Ankara, 06800, Turkey (Türkiye)
    Recruiting
  • Çanakkale Onsekiz Mart Üniversitesi Sağlık Araştırma ve Uygulama Hastanesi-Fiziksel Tıp ve Rehabilitasyon
    Kepez/Çanakkale Merkez/Çanakkale, 17110, Turkey (Türkiye)
    Recruiting
  • İnönü Üniversitesi Turgut Özal Tıp Merkezi Hastanesi-Fiziksel Tıp ve Rehabilitasyon
    Merkez/Battalgazi/Malatya, 44280, Turkey (Türkiye)
    Recruiting
  • Karadeniz Teknik Üniversitesi Farabi Hastanesi- Fiziksel Tıp ve Rehabilitasyon
    Trabzon Merkez/Ortahisar/Trabzon, 61080, Turkey (Türkiye)
    Recruiting
  • Adana Şehir Eğitim ve Araştırma Hastanesi-Fizik Tedavi ve Rehabilitasyon
    Yuregir/Adana, 01060, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Aug 2028, 28 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 28 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2026
First posted
Mar 19, 2026
StartActual
Apr 13, 2026
Primary completionEst.
Aug 14, 2028
CompletionEst.
Aug 14, 2028
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07481630
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 19, 2026
Start date
Apr 13, 2026
Primary completion
Aug 14, 2028 (estimated)
Completion
Aug 14, 2028 (estimated)
Last update
Jul 9, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zenagamtide

Start the discussion